Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' reply

Affiliations

Editorial

Christian Labenz et al. Aliment Pharmacol Ther. 2018 Dec.

. 2018 Dec;48(11-12):1318-1319.

doi: 10.1111/apt.15040.

¹ Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.

No abstract available

Comment on

Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, Galle PR, Wörns MA, Anstee QM, Schuppan D, Schattenberg JM. Labenz C, et al. Aliment Pharmacol Ther. 2018 Nov;48(10):1109-1116. doi: 10.1111/apt.14976. Epub 2018 Oct 4. Aliment Pharmacol Ther. 2018. PMID: 30288767
Editorial: stepwise risk stratification for both F3 and F4 fibrosis stage in NAFLD patients.
Idriss R, Lai M. Idriss R, et al. Aliment Pharmacol Ther. 2018 Dec;48(11-12):1317-1318. doi: 10.1111/apt.15024. Aliment Pharmacol Ther. 2018. PMID: 30488626 No abstract available.